Description:
Nintedanib is an intracellular tyrosine kinase inhibitor (TKI) with antifibrotic properties, which was one of the first drugs approved for use in idiopathic pulmonary fibrosis (IPF) and has more recently been approved for use in other chronic fibrosing ILDs a progressive phenotype and systemic sclerosis-associated ILD (SSc-ILD). Nintedanib significantly reduced the annual rate of decline in forced vital capacity (FVC) in adults with IPF, other progressive fibrosing ILDs and SSc-ILD.
Nintedanib also reduces the risk of events indicating ILD progression. Real-world experience in patients with IPF supports the effectiveness of nintedanib in slowing ILD progression. Nintedanib has a manageable tolerability profile in patients with fibrotic ILDs in clinical trials and real-world studies. Also, a long-term safety study is available for more than 4 years.
Share your experience with our medical product. Write a review!
22 Jul 2026
International Yoga Day 2026: How Yoga Promotes Wellness, Wisdom & Inner Peace
Yoga is more than a form of physical exercise. It is a holistic practice that connects the body, mind, and breath to support overall wellbeing. Every year, International Yoga Day encourages people aro
15 Jul 2026
World Brain Tumor Day 2026: Early Detection Awareness and the Need to Reduce Diagnostic Delays
World Brain Tumor Day is observed annually on 8 June to raise awareness about brain tumours, encourage early diagnosis, and support patients and families affected by these complex conditions.
15 Jun 2026
Hetero Healthcare on World No Tobacco Day 2026 - Unmasking the Appeal, Countering Addiction
Every year on May 31, the world comes together to observe World No Tobacco Day, a global initiative aimed at raising awareness about the dangers of tobacco use.
01 Jun 2026
Salt, Stress, and Sedentary Life: The Three Big Triggers of Hypertension
Every two seconds, somewhere in the world, a person suffers a heart attack or stroke linked to uncontrolled blood pressure.
